Aparna Naidu1, Michael P Malmquist2, Claude A Denham3, Sterling R Schow4. 1. Assistant Professor, Department of Diagnostic Sciences, Texas A&M University, Baylor College of Dentistry, Dallas, TX. Electronic address: aparna680@yahoo.com. 2. Resident, Department of Oral and Maxillofacial Surgery, Texas A&M University, Baylor College of Dentistry, Baylor University Medical Center, Dallas, TX. 3. Clinical Associate Professor, Texas A&M Health Science Center College of Medicine, Dallas TX; Department of Medical Oncology-Hematology, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX. 4. Professor, Department of Oral and Maxillofacial Surgery, Texas A&M University, Baylor College of Dentistry, Baylor University Medical Center, Dallas, TX.
Abstract
PURPOSE: In recent years, the treatment of central giant cell granuloma (CGCG) has become focused on the inhibition of osteoclast differentiation and proliferation. Medications that were developed for the treatment of giant cell tumor of bone and bone resorption from metastatic skeletal disease have shown some success in the treatment of CGCG. The present report describes 2 cases of CGCG of the mandible that were treated effectively with subcutaneous denosumab. MATERIALS AND METHODS: Two cases of histologically diagnosed CGCG of the mandible were treated with monthly subcutaneous injections of denosumab 120 mg primarily or after intralesional corticosteroid therapy. Clinical and radiographic follow-ups were recorded over a period of 24 months (case 1) and 15 months (case 2). RESULTS: In the 2 cases, progressive radiodensity and osseous regeneration were noted 4 to 6 months after denosumab therapy was initiated. A decrease in lesion size and improvement in bone contour and facial symmetry were seen in the 2 cases. CONCLUSION: The major radiographic, clinical, and histologic responses seen in these 2 cases suggest that denosumab may represent a viable alternative or adjunctive procedure to eliminate or decrease the extent of surgical intervention and morbidity in the treatment of CGCG. Future prospective studies with a larger sample would provide more comprehensive information about the long-term effects and possible adverse side effects of treating CGCG of the jaws with denosumab.
PURPOSE: In recent years, the treatment of central giant cell granuloma (CGCG) has become focused on the inhibition of osteoclast differentiation and proliferation. Medications that were developed for the treatment of giant cell tumor of bone and bone resorption from metastatic skeletal disease have shown some success in the treatment of CGCG. The present report describes 2 cases of CGCG of the mandible that were treated effectively with subcutaneous denosumab. MATERIALS AND METHODS: Two cases of histologically diagnosed CGCG of the mandible were treated with monthly subcutaneous injections of denosumab 120 mg primarily or after intralesional corticosteroid therapy. Clinical and radiographic follow-ups were recorded over a period of 24 months (case 1) and 15 months (case 2). RESULTS: In the 2 cases, progressive radiodensity and osseous regeneration were noted 4 to 6 months after denosumab therapy was initiated. A decrease in lesion size and improvement in bone contour and facial symmetry were seen in the 2 cases. CONCLUSION: The major radiographic, clinical, and histologic responses seen in these 2 cases suggest that denosumab may represent a viable alternative or adjunctive procedure to eliminate or decrease the extent of surgical intervention and morbidity in the treatment of CGCG. Future prospective studies with a larger sample would provide more comprehensive information about the long-term effects and possible adverse side effects of treating CGCG of the jaws with denosumab.
Authors: Raíssa Pinheiro de Mendonça; Geovanni Pereira Mitre; Flavio Henrique Real; Maria Sueli da Silva Kataoka; Sérgio de Melo Alves Júnior; Paulo Vianna; Newton Guerreiro Da Silva Júnior; João de Jesus Viana Pinheiro Journal: Head Neck Pathol Date: 2019-07-11
Authors: Yoon Ji Jina Rhou; Che-Jen Wang; Minh Nguyen; Joel A Vanderniet; Craig F Munns; Hedley Coleman; James Kim; Deborah Jane Holmes-Walker; Lydia Lim; Christian M Girgis Journal: Calcif Tissue Int Date: 2022-01-28 Impact factor: 4.333
Authors: Eelis Rytkönen; Vuokko Ottavainen; Aleksi Rytkönen; Sanna Uusitalo; Petri Lehenkari; George K Sándor Journal: Ann Maxillofac Surg Date: 2018 Jul-Dec
Authors: Alexander Upfill-Brown; Susan Bukata; Nicholas M Bernthal; Alan L Felsenfeld; Scott D Nelson; Arun Singh; Katherine Wesseling-Perry; Fritz C Eilber; Noah C Federman Journal: JBMR Plus Date: 2019-08-22